HCSG HEALTHCARE SERVICES GROUP INC
AI brief AI-written, not reviewed by a person
Latest figures show cash and equivalents of 134,598,000 USD at 2026-09-30, stockholders’ equity of 531,451,000 USD at 2026-09-30, and revenue of 1,837,173,000 USD for the year to 2025-12-31, with diluted EPS (year) for 12 months to 2025-12-31 of 0.81 USD and diluted EPS (quarter) for 3 months to 2026-09-30 of 0.36 USD. The sources also provide quarter and year figures for net income, operating cash flow, and other balance sheet items through similar dates, enabling comparative analysis against prior periods stated in the same filings. No projections or external targets are provided in the cited material; all figures are as reported in the SEC filings referenced.
- Cash and equivalents declined from 136,172,000 USD (2026-03-31) to 134,598,000 USD (2026-09-30), per filings. [1]
- Stockholders' equity increased to 531,451,000 USD at 2026-09-30 from 518,842,000 USD at 2026-06-30 [1]
- Revenue (year) for 12 months to 2025-12-31 was 1,837,173,000 USD, up from 1,715,682,000 USD for 12 months to 2024-12-31 [1]
- Diluted EPS (year) for 12 months to 2025-12-31 was 0.81 USD per share, versus 0.53 USD for 12 months to 2024-12-31 [1]
- Net income (year) for 12 months to 2025-12-31 was 59,059,000 USD, versus 39,471,000 USD for 12 months to 2024-12-31 [1]
- Operating cash flow (year) for 12 months to 2025-12-31 was 144,968,000 USD, versus 30,802,000 USD for 12 months to 2024-12-31 [1]
Written by OpenVibe.AI from the SEC numbers and filings on this page, not reviewed by a person. Informational only; not investment advice. Written from figures and filings up to (gpt-5-nano-2025-08-07).
What the sources did not support
- No explicit market or filing context beyond the presented SEC data; no commentary on trends, multiples, or industry context is provided in the sources.
- Observation items rely on selected lines; some other items (e.g., quarterly EPS, quarterly revenue trends) exist but are not incorporated into observations unless they are directly cited in the provided text.
Observations
| Metric | Value | Observed | Source | Retrieved | Freshness |
|---|---|---|---|---|---|
| Revenue (quarter) (3 months to 2026-09-30) | 479,604,000 USD | sec-companyfacts | current | ||
| Revenue (year) (12 months to 2025-12-31) | 1,837,173,000 USD | sec-companyfacts | current | ||
| Net income (quarter) (3 months to 2026-09-30) | 24,877,000 USD | sec-companyfacts | current | ||
| Net income (year) (12 months to 2025-12-31) | 59,059,000 USD | sec-companyfacts | current | ||
| Diluted EPS (quarter) (3 months to 2026-09-30) | 0.36 USD/shares | sec-companyfacts | current | ||
| Diluted EPS (year) (12 months to 2025-12-31) | 0.81 USD/shares | sec-companyfacts | current | ||
| Operating cash flow (quarter) (3 months to 2026-03-31) | 43,730,000 USD | sec-companyfacts | current | ||
| Operating cash flow (year) (12 months to 2025-12-31) | 144,968,000 USD | sec-companyfacts | current | ||
| Total assets (at 2026-09-30) | 850,398,000 USD | sec-companyfacts | current | ||
| Stockholders' equity (at 2026-09-30) | 531,451,000 USD | sec-companyfacts | current | ||
| Cash and equivalents (at 2026-09-30) | 134,598,000 USD | sec-companyfacts | current | ||
| Shares outstanding (at 2026-10-21) | 67,432,007 shares | sec-companyfacts | current |
Context
No reviewed context has been published for HCSG. The observations and documents below are shown as their sources stated them.
Documents
Source freshness
| Source | Freshness | Last successful fetch | Stale after | Sources reports |
|---|---|---|---|---|
| SEC EDGAR: company financial facts (XBRL) sec-companyfacts | current | 10080 min | ok | |
| SEC EDGAR: latest XBRL filings sec-xbrl-filings | current | 45 min | healthy |
Watch this instrument
Sign in to add HCSG to a private watchlist or to get an alert when a new document or observation arrives.
Machine-readable: HCSG.json (the same data with every timestamp and source).
Information only — not investment advice; no trading here. OpenVibe.Trade holds no money or assets, takes no orders and gives no personal recommendations.